

4<sup>th</sup> February, 2026

<b>To,</b> <b>The General Manager</b> <b>Department of Corporate Services</b> <b>BSE Ltd.</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.  <b>Ref.: Scrip Code No. : 540701 (Equity)</b> <b>: 975834, 976560 and 977467 (Debt)</b>	<b>To,</b> <b>The Manager,</b> <b>Listing Department,</b> <b>National Stock Exchange of India Ltd.</b> “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.  <b>Ref. : (i) Symbol – DCAL</b> <b>(ii) Series – EQ</b>
--	--

**SUB: PRESS RELEASE ON UN-AUDITED FINANCIAL RESULT FOR THE THIRD QUARTER ENDED 31<sup>ST</sup> DECEMBER, 2025 – REGULATIONS: 30 and 51**

Dear Sir,

Pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, kindly find enclosed herewith Press Release on financial result for the third quarter ended 31<sup>st</sup> December, 2025.

The aforesaid Press Release is also being hosted on the website of the Company, [www.imdcal.com](http://www.imdcal.com) in accordance with the Regulations 46 and 62 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Kindly take the same on your record.

Thanking You,

Yours faithfully,

**For, Dishman Carbogen Amcis Limited**

**Shrima Dave**  
**Company Secretary**

Encl.: As above

## Dishman Carbogen Amcis Ltd. announces Q3 & 9MFY26 CONSOLIDATED 9MFY26 NET REVENUE AT **RS. 20,805 million**

**Ahmedabad, India – February 04, 2025** – Dishman Carbogen Amcis Ltd, a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies, announces their Q3 & 9MFY26 results.

### Financial performance

Consolidated Q3FY26 review

- Q3FY26 Net revenue at Rs. 7,198 mn vs Rs. 6,823 mn in Q3FY25  
9MFY26 Net revenue at Rs. 20,805 mn vs Rs. 19,952 mn in 9MFY25
- Q3FY26 EBITDA at Rs. 1,131 mn vs Rs. 1,401 mn in Q3FY25  
9MFY26 EBITDA at Rs. 4,027 mn vs Rs. 3,163 mn in 9MFY25
- Q3FY26 EBITDA Margin at 15.7% vs 20.5% in Q3FY25  
9MFY26 EBITDA Margin at 19.4% vs 15.9% in 9MFY25

REVENUE (Rs mn)	Q3FY26	Q3FY25	YoY %	9MFY26	9MFY25	YoY %
CDMO	6,297.4	5,901.0	6.7%	17,503.8	17,234.4	1.6%
Marketable Molecules	900.6	922.3	-2.4%	3,301.2	2,717.2	21.5%
Grand Total	7,198.0	6,823.3		20,805.0	19,951.6	

### Q3 & 9MFY26 Result Highlights

- Net Revenue at Rs.7,198 mn in Q3FY26 up by 5.5% as compared to Rs. 6,823 mn in Q3FY25 mainly due to higher revenue from CDMO segment.
- Net Revenue at Rs.20,805 mn in 9MFY26 up by 4.3% as compared to Rs. 19,952 mn in 9MFY25 mainly due to higher Cholesterol and Vitamin D analogues revenue contribution.
- CDMO revenue for Q3FY26 is higher by 6.7% compared to Q3FY25 and marginally higher by 1.6% YoY in 9MFY26 primarily due to higher development revenue.
- Marketable Molecules (MM) segment revenue for Q3FY26 decreased by 2.4% as compared to Q3FY25 primarily due to lower Quats revenue and MM revenue increased by 21.5% in 9MFY26 mainly due to increase in Cholesterol and Vitamin D analogues supplies.



- EBITDA Margin at 15.7% in Q3FY26 compared to 20.5% in Q3FY25 mainly due to
  - Decrease in margins in CDMO segment from 22.1% to 16.9% QoQ due to lower contribution from late Phase III molecules.
  - Decrease in margins in MM segment from 11.3% to 7.2% QoQ due to high composition of cholesterol revenue.
- EBITDA Margin at 19.4% in 9MFY26 compared to 15.9% in 9MFY25 mainly due to
  - Increase in margins in CDMO segment from 17.2% to 19.7% YOY due to higher revenue contribution from late Phase III molecules.
  - Increase in margins in MM segment from 8.3% to 17.5% YoY is due to higher supplies of Vitamin D analogues and continued cost reduction measures.
- Supplies of approximately Rs. 20 crores were deferred from Q3FY26 to Q4FY26 due to late supplies of intermediates and holiday period in Europe.

## About Dishman Carbogen Amcis Ltd.

Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CDMO (Contract Development and Manufacturing Organisation) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical companies. The Company has global presence with development and manufacturing sites in Switzerland, UK, France, Netherlands, India, and China.

Dishman provides end-to-end integrated high-value niche CDMO offering and has comprehensive product offerings which include APIs, High Potent APIs, Intermediates, Phase Transfer Catalysts, Vitamin D Analogues, Cholesterol, Lanolin-related products, Antiseptic and Disinfectant formulations. For details, please visit [www.imdcal.com](http://www.imdcal.com).

## For details please contact:

### Harshil Dalal

Group CFO

P: +91 22 22867597

E: [harshil.dalal@dishmangroup.com](mailto:harshil.dalal@dishmangroup.com)

### Krishna Patel

Ernst & Young LLP

P: +91 9998236402

E: [krishna.patel2@in.ey.com](mailto:krishna.patel2@in.ey.com)